Indocyanine green molecular angiography of choroidal neovascularization.


Journal

Experimental eye research
ISSN: 1096-0007
Titre abrégé: Exp Eye Res
Pays: England
ID NLM: 0370707

Informations de publication

Date de publication:
03 2019
Historique:
received: 23 10 2018
revised: 03 12 2018
accepted: 20 12 2018
pubmed: 26 12 2018
medline: 7 5 2019
entrez: 25 12 2018
Statut: ppublish

Résumé

Retinal diseases such as proliferative diabetic retinopathy and neovascular AMD are characterized by the formation of new blood vessels. Current imaging techniques such as fluorescein and ICG angiography help to identify areas of vascular leakage but are limited in their applicability due to their nonspecific nature. However, as new treatment paradigms emerge in an effort to have patient specific treatments, the development of new imaging techniques that are capable of identifying patient specific biomarkers will become crucial for the success of these approaches. In this study, we create and characterize an endoglin (CD105) targeted imaging probe that can be used for indocyanine green (ICG) molecular angiography. This anti-endoglin-ICG bioconjugate has a self-quenching "off-on" capacity to enable high contrast imaging of proliferative blood vessels at a molecular level in vivo. Using the laser CNV mouse model we demonstrate an approximate 3-fold increase in lesion visualization compared to non-targeting controls.

Identifiants

pubmed: 30582913
pii: S0014-4835(18)30784-X
doi: 10.1016/j.exer.2018.12.016
pii:
doi:

Substances chimiques

Coloring Agents 0
Endoglin 0
Eng protein, mouse 0
Indocyanine Green IX6J1063HV

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

122-128

Informations de copyright

Copyright © 2018. Published by Elsevier Ltd.

Auteurs

Derrick J Feenstra (DJ)

Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Ltd., Basel, Switzerland.

Muharrem Seleci (M)

Institute of Technical Chemistry, Leibniz University of Hanover, Hanover, Germany.

Nora Denk (N)

Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Ltd., Basel, Switzerland.

Sascha Fauser (S)

Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Ltd., Basel, Switzerland.

Faye M Drawnel (FM)

Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Ltd., Basel, Switzerland.

Ashwath Jayagopal (A)

Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Ltd., Basel, Switzerland. Electronic address: ashwath.jayagopal@roche.com.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH